772 related articles for article (PubMed ID: 24559766)
1. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
[TBL] [Abstract][Full Text] [Related]
2. Real-World Clinical Practice of Intensified Chemotherapies for Metastatic Pancreatic Cancer: Results from a Pan-European Questionnaire Study.
Le N; Vinci A; Schober M; Krug S; Javed MA; Kohlmann T; Sund M; Neesse A; Beyer G
Digestion; 2016; 94(4):222-229. PubMed ID: 28030863
[TBL] [Abstract][Full Text] [Related]
3. Comparison of treatment patterns, resource utilization, and cost of care in patients with metastatic pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine or FOLFIRINOX.
Kim GP; Parisi MF; Patel MB; Pelletier CL; Belk KW
Expert Rev Clin Pharmacol; 2017 May; 10(5):559-565. PubMed ID: 28286977
[TBL] [Abstract][Full Text] [Related]
4. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
Ellenrieder V; König A; Seufferlein T
Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
[TBL] [Abstract][Full Text] [Related]
5. Improvement of Treatment Outcomes for Metastatic Pancreatic Cancer: A Real-world Data Analysis.
Sasaki T; Kanata R; Yamada I; Matsuyama M; Ozaka M; Sasahira N
In Vivo; 2019; 33(1):271-276. PubMed ID: 30587635
[TBL] [Abstract][Full Text] [Related]
6. Patterns of Chemotherapy Use in a U.S.-Based Cohort of Patients with Metastatic Pancreatic Cancer.
Abrams TA; Meyer G; Meyerhardt JA; Wolpin BM; Schrag D; Fuchs CS
Oncologist; 2017 Aug; 22(8):925-933. PubMed ID: 28476943
[TBL] [Abstract][Full Text] [Related]
7. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
8. Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX.
McBride A; Bonafede M; Cai Q; Princic N; Tran O; Pelletier C; Parisi M; Patel M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1153-1160. PubMed ID: 28795609
[TBL] [Abstract][Full Text] [Related]
9. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.
Chllamma MK; Cook N; Dhani NC; Giby K; Dodd A; Wang L; Hedley DW; Moore MJ; Knox JJ
Br J Cancer; 2016 Sep; 115(6):649-54. PubMed ID: 27467054
[TBL] [Abstract][Full Text] [Related]
11. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
[TBL] [Abstract][Full Text] [Related]
12. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX).
Rinaldi Y; Pointet AL; Khemissa Akouz F; Le Malicot K; Wahiba B; Louafi S; Gratet A; Miglianico L; Laharie H; Bouhier Leporrier K; Thirot Bidault A; Texereau P; Coriat R; Terrebonne E; Gouttebel MC; Malka D; Bachet JB; Lepage C; Taieb J;
Eur J Cancer; 2020 Sep; 136():25-34. PubMed ID: 32623182
[TBL] [Abstract][Full Text] [Related]
13. Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis.
El Rassy E; Assi T; El Karak F; Ghosn M; Kattan J
Clin Res Hepatol Gastroenterol; 2017 Mar; 41(2):e26-e28. PubMed ID: 28215539
[No Abstract] [Full Text] [Related]
14. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
15. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
[TBL] [Abstract][Full Text] [Related]
16. Successful treatment with nab-paclitaxel and gemcitabine after FOLFIRINOX failure in a patient with metastasized pancreatic adenocarcinoma.
Berger AK; Weber TF; Jäger D; Springfeld C
Onkologie; 2013; 36(12):763-5. PubMed ID: 24356569
[TBL] [Abstract][Full Text] [Related]
17. Nab-paclitaxel and gemcitabine or FOLFIRINOX as first-line treatment in patients with unresectable adenocarcinoma of the pancreas: does sequence matter?
Vogl UM; Andalibi H; Klaus A; Vormittag L; Schima W; Heinrich B; Kafka A; Winkler T; Öhler L
BMC Cancer; 2019 Jan; 19(1):28. PubMed ID: 30621630
[TBL] [Abstract][Full Text] [Related]
18. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
19. Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.
Klein-Brill A; Amar-Farkash S; Lawrence G; Collisson EA; Aran D
JAMA Netw Open; 2022 Jun; 5(6):e2216199. PubMed ID: 35675073
[TBL] [Abstract][Full Text] [Related]
20. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H
Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]